Soc. Generale Knock-Out AYJ/ DE000SU15AA3 /
7/5/2024 5:29:50 PM | Chg.+0.010 | Bid5:30:09 PM | Ask- | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
4.110EUR | +0.24% | - Bid Size: - |
- Ask Size: - |
VALNEVA SE EO... | 7.3284 EUR | 12/31/2078 | Put |
GlobeNewswire
7/1
Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ...
GlobeNewswire
6/26
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Direct...
GlobeNewswire
6/24
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
GlobeNewswire
6/5
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Co...
GlobeNewswire
6/3
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire
5/13
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...
GlobeNewswire
5/7
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
3/25
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
GlobeNewswire
3/21
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th Wo...
GlobeNewswire
3/18
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and Orbi...
GlobeNewswire
3/4
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
GlobeNewswire
2/29
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHI...
GlobeNewswire
1/10
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
GlobeNewswire
1/4
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Foru...
GlobeNewswire
12/4/2023
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, ...